2[4]Hirakata Y, Izumikawa K, Yamaguchi K, et al.Rapid detection and evolution of clinical characteristics of emerging multiple-drug-resistant Gram-negative rods carrying the metallo-β-lactamase gene blaIMP[J]. Antimicrob Agents Chemother, 1998, 42: 2006-2011.
3[5]Arakawa Y, Shibata N, Shibayama K, et al. Convenient test for screening metallo-β-lactamase-producing Gram-negative bacteria by using thiol compounds[J]. J Clin Microbiol, 2000, 38(1): 40-43.
4[6]National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard[S]. Fifth edition. Wayne Pennsylvania National Committee for Clinical Laboratory Standards. 2001.
5[7]Saino Y, Kobayash F, Inoue M, et al. Purification and properties of inducible penicillin-beta-lactamase isolates from Pseudomonas maltophilia[J]. Antimicrob Agents Chemother, 1982, 22: 564-570.
6[8]Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems[J]. Antimicrob Agents Chemother, 1996, 40(2): 349-353.
7Poirel L,Naas T,Nicolas D,et al. Characterization of VIM-2,a carbapenem-hydrolyzing metallo-β-lactamases and its plasmid and integron-gene from a Pseudomonas aeruginosa clinical isolate in France[J]. Antimicrob Agents Chemother, 2000,44(4):891-897.
8Yan JJ,Hsueh PR,Ko WC,et al. Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3,a novel variant of the VIM-2 enzyme[J]. Antimicrob Agents Chemother, 2001,45(8):2224-2228.
9Iyobe S,Kusadokoro H,Ozaki J,et al. Amino acid substitutions in a variant of IMP-1 metallo-beta-lactamases[J]. Antimicrob Agents Chemother, 2000,44(8):2023-2027.
10Docquierm JD, Lamotte-Brasseur J, Galleni M. On functional and structural heterogeneity of VIM-type metallo-β-lactamases[J]. J Antimicrob Chemother, 2003, 51(2):257-266.
